Overview
Applying Institutional Susceptibility Data in Treatment Decisions for HAP/VAP
HAP/VAP due to P. aeruginosa: An ID Pharmacy Case Review
Click the"View Activity" button to view this activity.
View ActivityActivity already occured. CME/CE is no longer available for this activity
Are you an infectious disease (ID) pharmacist? Want to learn more about hospital- and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa? This webcast is for you!
Developed in collaboration with Making a Difference in Infectious Disease (MAD-ID), expert ID pharmacists Jim Lewis and Jason Pogue discuss the latest strategies to treat HAP/VAP and mitigate antibiotic resistance. This webcast features a patient case to help learners incorporate the latest antimicrobial therapy while optimizing long-term outcomes and resistance patterns for hospital- and ventilator-associated pneumonia (HAP/VAP) due to P. aeruginosa.
This activity is intended for pharmacists and infectious disease specialists who care for patients at risk of serious infection.
Antibacterial resistance persists as a major threat to public health; in fact, 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. Antibacterial resistance can be present in any type of bacterial infection, including both HAP and VAP. The combination of HAP and VAP alone constitutes the most common cause of death among all hospital-acquired infections, with mortality rates up to 33%. Therefore, it is imperative that pharmacists involved in HAP/VAP care understand 1) the epidemiology of antibiotic resistance, 2) the key characteristics of the Gram-negative antibiotic armamentarium, and 3) optimal antimicrobial implementation strategies.
Upon completion of this activity, participants will be able to:
• Demonstrate an understanding of the molecular epidemiology of antibiotic resistance in bacterial pathogens
• Summarize the salient features and critical differences between the antibiotics for use against Gram-negative pathogens
• Describe strategies to optimize antimicrobial therapy to ensure effectiveness of antibiotics and reduce resistance
I. Introduction and Background
II. Risk Factors and Microbiology
III. IDSA and ERS/ESCMID/ALAT recommendations
IV. HAP/VAP Armamentarium
V. Resistance Considerations
II. Risk Factors and Microbiology
III. IDSA and ERS/ESCMID/ALAT recommendations
IV. HAP/VAP Armamentarium
V. Resistance Considerations
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Merck & Company.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
James Lewis, II, PharmD, FIDSA
Infectious Disease Clinical Pharmacy Supervisor
Co-Director of Antibiotic Stewardship
Department of Pharmacy
Oregon Health & Science University
Portland, OR
Infectious Disease Clinical Pharmacy Supervisor
Co-Director of Antibiotic Stewardship
Department of Pharmacy
Oregon Health & Science University
Portland, OR
Jason M. Pogue, PharmD, BCPS, BCIDP
Clinical Professor, Infectious Diseases
Department of Clinical Pharmacy
University of Michigan College of Pharmacy
Ann Arbor, MI
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CPE activity.
The following financial relationships have been provided:
James Lewis II, PharmD
Consultant: Merck & Company
Jason Pogue, PharmD
Consultant: Merck & Company, Shionogi
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CPE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 75 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 1.25 contact hours
ACPE Universal Activity Number: 0396-0000-20-044-H01-P
Activity Type: Knowledge
ACPE Universal Activity Number: 0396-0000-20-044-H01-P
Activity Type: Knowledge